menu
    • menu
    [{"orgOrder":0,"company":"Evolus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Prabotulinumtoxin A","moa":"Ach release","graph1":"Dermatology","graph2":"Phase III","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Evolus \/ Not Applicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"Ach release","graph1":"Dermatology","graph2":"Approved","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Evolus \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Evolus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"Ach release","graph1":"Dermatology","graph2":"Approved","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evolus \/ Not Applicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"Ach release","graph1":"Dermatology","graph2":"Approved","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evolus \/ Not Applicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"Ach release","graph1":"Dermatology","graph2":"Approved","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evolus \/ Not Applicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Prabotulinumtoxin A","moa":"Ach release","graph1":"Dermatology","graph2":"Approved","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evolus \/ Not Applicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"SNAP-25","graph1":"Dermatology","graph2":"Approved","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Evolus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evolus \/ Not Applicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"SNAP-25","graph1":"Dermatology","graph2":"Approved","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Evolus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evolus \/ Not Applicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA-Xvfs","moa":"SNAP-25","graph1":"Dermatology","graph2":"Approved","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Evolus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evolus \/ Not Applicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Evolus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evolus \/ Not Applicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Evolus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evolus \/ Not Applicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Evolus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evolus \/ Not Applicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA-xvfs","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Evolus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evolus \/ Not Applicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Evolus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evolus \/ Not Applicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"PrabotulinumtoxinA-xvfs","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Evolus","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Evolus \/ Leerink Partners","highestDevelopmentStatusID":"12","companyTruncated":"Evolus \/ Leerink Partners"},{"orgOrder":0,"company":"Evolus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Evolus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evolus \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Evolus

    Menu

    Evolus

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Evolus

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Evolus

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Botulinum toxin type A

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Evolus Launches Nuceiva in Spain for Botulinum Toxin Type A

                            Details : Nuceiva (prabotulinumtoxinA) is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines.

                            Brand Name : Nuceiva

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 12, 2024

                            Lead Product(s) : Botulinum toxin type A

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Evolus

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Evolus

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PrabotulinumtoxinA-xvfs

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Leerink Partners

                            Deal Size : $50.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock

                            Details : Proceeds will support the commercialization of Jeuveau (prabotulinumtoxinA-xvfs), an ACH release inhibitor for improving glabellar lines.

                            Brand Name : Jeuveau

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 11, 2024

                            Lead Product(s) : PrabotulinumtoxinA-xvfs

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Leerink Partners

                            Deal Size : $50.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Evolus

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Evolus

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PrabotulinumtoxinA

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Evolus Initiates Nuceiva® Launch in Germany and Austria

                            Details : Nuceiva (prabotulinumtoxinA) blocks peripheral acetylcholine release at presynaptic cholinergic nerve terminals by cleaving SNAP-25, a protein integral to the successful docking and release of acetylcholine thereby leading to denervation of the muscle an...

                            Brand Name : Nuceiva

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 27, 2023

                            Lead Product(s) : PrabotulinumtoxinA

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Evolus

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Evolus

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PrabotulinumtoxinA-xvfs

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            "Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase II Data Resul...

                            Details : Jeuveau (prabotulinumtoxinA) blocks peripheral acetylcholine release at presynaptic cholinergic nerve terminals by cleaving SNAP-25, a protein integral to the successful docking and release of acetylcholine thereby leading to denervation of the muscle an...

                            Brand Name : Jeuveau

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 28, 2023

                            Lead Product(s) : PrabotulinumtoxinA-xvfs

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Evolus

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Evolus

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PrabotulinumtoxinA

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Evolus Receives Regulatory Approval for Nuceiva® in Australia

                            Details : Nuceiva (prabotulinumtoxinA) blocks peripheral acetylcholine release at presynaptic cholinergic nerve terminals by cleaving SNAP-25, a protein integral to the successful docking and release of acetylcholine thereby leading to denervation of the muscle an...

                            Brand Name : Nuceiva

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 23, 2023

                            Lead Product(s) : PrabotulinumtoxinA

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Evolus

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Evolus

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PrabotulinumtoxinA

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Evolus to Present Phase 2 Interim Data from Jeuveau® “Extra-Strength” Dose for Extended Duration Study at...

                            Details : Jeuveau (prabotulinumtoxinA) blocks peripheral acetylcholine release at presynaptic cholinergic nerve terminals by cleaving SNAP-25, a protein integral to the successful docking and release of acetylcholine thereby leading to denervation of the muscle an...

                            Brand Name : Jeuveau

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 23, 2023

                            Lead Product(s) : PrabotulinumtoxinA

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Evolus

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Evolus

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PrabotulinumtoxinA

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Evolus Broadens Its International Presence with Nuceiva® Launch in Great Britain

                            Details : Nuceiva® (botulinum toxin type A) is approved for temporary improvement in the appearance of moderate to severe vertical lines between eyebrows seen at maximum frown, when severity of facial lines has an important psychological impact in adults below 65...

                            Brand Name : Nuceiva

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 04, 2022

                            Lead Product(s) : PrabotulinumtoxinA

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Evolus

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Evolus

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PrabotulinumtoxinA-Xvfs

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Newly Published Post Hoc Analysis Evaluates Efficacy of Jeuveau® in Adult Males Compared to BOTOX®

                            Details : Peer-reviewed, post hoc analysis published in Aesthetic Surgery Journal showed with high consistency that males treated with Jeuveau® (prabotulinumtoxinA-xvfs), neurotoxin product, had higher responder rates than those treated with BOTOX across nearly a...

                            Brand Name : Jeuveau

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 24, 2022

                            Lead Product(s) : PrabotulinumtoxinA-Xvfs

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Evolus

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Evolus

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PrabotulinumtoxinA

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Evolus Successfully Completes Patient Enrollment in Phase II Clinical Study Evaluating “Extra-Strength” Do...

                            Details : Jeuveau (prabotulinumtoxinA) is approved for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines) in adults below 65 years of age.

                            Brand Name : Jeuveau

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 12, 2022

                            Lead Product(s) : PrabotulinumtoxinA

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Evolus

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Evolus

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PrabotulinumtoxinA

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Peer-Reviewed Post Hoc Analysis Shows Jeuveau® is Highly Effective for Millennials by All Measures and at All...

                            Details : The data showed Jeuveau® (prabotulinumtoxinA-xvfs) was well tolerated in both millennial and non-millennial patient populations, and highly effective for millennials with moderate-to-severe glabellar lines.

                            Brand Name : Jeuveau

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 02, 2022

                            Lead Product(s) : PrabotulinumtoxinA

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth